Cargando…
P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171564/ http://dx.doi.org/10.1097/01.HS9.0000936268.48048.d9 |
| _version_ | 1785039446019670016 |
|---|---|
| author | Einsele, H. Dhakal, B. Schecter, J. M. Roccia, T. Deraedt, W. Lendvai, N. Slaughter, A. Lonardi, C. Connors, K. Qi, K. Londhe, A. Carson, R. Voelker, J. Cost, P. Valluri, S. Florendo, E. Pacaud, L. Yong, K. |
| author_facet | Einsele, H. Dhakal, B. Schecter, J. M. Roccia, T. Deraedt, W. Lendvai, N. Slaughter, A. Lonardi, C. Connors, K. Qi, K. Londhe, A. Carson, R. Voelker, J. Cost, P. Valluri, S. Florendo, E. Pacaud, L. Yong, K. |
| author_sort | Einsele, H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171564 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101715642023-05-11 P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY Einsele, H. Dhakal, B. Schecter, J. M. Roccia, T. Deraedt, W. Lendvai, N. Slaughter, A. Lonardi, C. Connors, K. Qi, K. Londhe, A. Carson, R. Voelker, J. Cost, P. Valluri, S. Florendo, E. Pacaud, L. Yong, K. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171564/ http://dx.doi.org/10.1097/01.HS9.0000936268.48048.d9 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Einsele, H. Dhakal, B. Schecter, J. M. Roccia, T. Deraedt, W. Lendvai, N. Slaughter, A. Lonardi, C. Connors, K. Qi, K. Londhe, A. Carson, R. Voelker, J. Cost, P. Valluri, S. Florendo, E. Pacaud, L. Yong, K. P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY |
| title | P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY |
| title_full | P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY |
| title_fullStr | P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY |
| title_full_unstemmed | P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY |
| title_short | P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY |
| title_sort | p35 analysis of daratumumab clinical trials: characteristics and outcomes in patients with lenalidomide-refractory relapsed/refractory multiple myeloma treated with 1-3 prior lines of therapy |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171564/ http://dx.doi.org/10.1097/01.HS9.0000936268.48048.d9 |
| work_keys_str_mv | AT einseleh p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT dhakalb p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT schecterjm p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT rocciat p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT deraedtw p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT lendvain p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT slaughtera p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT lonardic p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT connorsk p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT qik p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT londhea p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT carsonr p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT voelkerj p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT costp p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT valluris p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT florendoe p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT pacaudl p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy AT yongk p35analysisofdaratumumabclinicaltrialscharacteristicsandoutcomesinpatientswithlenalidomiderefractoryrelapsedrefractorymultiplemyelomatreatedwith13priorlinesoftherapy |